AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial

Results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors. These results, which include the first progression-free survival and overall survival findings reported from the trial, were presented today at the 2023 European Society for Medical Oncology Congress in Madrid, Spain and simultaneously published in the Journal of Clinical Oncology. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca (AZN) and Daiichi Sankyo (DSNKY). In the primary analysis, ENHERTU demonstrated a median PFS of 6.9 months and a median OS of 13.4 months in the overall trial population of previously treated patients with HER2-expressing advanced solid tumors, including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic cancers or other tumors, as assessed by investigator. ENHERTU also continued to show a confirmed objective response rate of 37.1% and a median duration of response of 11.3 months in these patients.